According to a small study by Weill Cornell Medicine and New York-Presbyterian investigators, vaccinating mothers using Pfizer Inc's (NYSE:PFE) vaccine against respiratory syncytial virus (RSV) during late pregnancy to protect their newborns is not associated with an increased risk of preterm birth or other poor outcomes.
The FDA approved the Abrysvo (RSVpreF) vaccine last year. It targets women in their second or third trimesters to prevent RSV infections in newborns during their first six months.
Also Read: UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract.
In September 2023, the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended the RSVpreF vaccine be administered to most pregnant individuals from September to January in the U.S.
This is in contrast to GSK Plc's (NYSE:GSK) RSV adjuvanted vaccine, which is not approved for use in pregnant individuals based on a trial that was terminated early due to an elevated risk of premature birth and associated neonatal deaths.
Although the FDA approved the RSVpreF vaccine, the gestational age window was limited to 32 0/7 to 36 6/7 weeks due to concerns about the numerical difference in preterm birth among participants who received the RSVpreF vaccine from 24 to 36 weeks gestation.
The findings indicated no significant statistical difference in preterm birth rates, with vaccinated women showing a rate of 5.9%, compared to 6.7% in unvaccinated women.
The study analyzed electronic health records from two New York City hospitals, focusing on births from September 2023 to late January 2024.
Data published in the Jama Network comes from 2,973 pregnant individuals. The researchers add that though the data support the safety of prenatal RSVpreF vaccination, further investigation into the risk of hypertensive disorders of pregnancy (HDP) is warranted.
Price Action: PFE shares are down 0.60% at $27.88 at the last check on Monday.
- CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK.
Photo via Shutterstock
根据Weill Cornell Medicine和纽约长老会调查人员进行的一项小型研究，母亲在妊娠晚期使用辉瑞公司（纽约证券交易所代码：PFE）的呼吸道合胞病毒（RSV）疫苗接种以保护新生儿与早产风险增加或其他不良预后无关。
美国食品药品管理局去年批准了Abrysvo（RsvPref）疫苗。它针对的是孕中期或晚期的女性，以防止新生儿在头六个月内感染呼吸道合胞病毒。
另请阅读：英国选择辉瑞而不是葛兰素史克签订数百万剂量的呼吸道合约。
2023年9月，美国疾病控制与预防中心的免疫实践咨询委员会建议，在9月至1月，在美国向大多数孕妇接种RSVPref疫苗。
这与葛兰素史克公司（纽约证券交易所代码：GSK）的呼吸道合胞病毒辅助疫苗形成鲜明对比。根据一项试验，该试验因早产和相关新生儿死亡的风险升高而提前终止，该疫苗未获准用于孕妇。
尽管美国食品和药物管理局批准了RSVPref疫苗，但由于担心在妊娠24至36周之间接种RSVPref疫苗的参与者之间的早产数字差异，胎龄窗口限制在32 0/7至36 6/7周以内。
研究结果表明，早产率没有显著的统计差异，接种疫苗的女性的早产率为5.9％，而未接种疫苗的女性的早产率为6.7％。
该研究分析了纽约市两家医院的电子健康记录，重点是2023年9月至2024年1月下旬的出生情况。
Jama网络上发布的数据来自2973名孕妇。研究人员补充说，尽管数据支持产前RsvPref疫苗的安全性，但有必要进一步调查妊娠期高血压障碍（HDP）的风险。
价格走势：周一最后一次支票时，PFE股价下跌0.60％，至27.88美元。
- CDC顾问小组建议美国75岁以上人群接种呼吸道合胞病毒疫苗，分析师称GsK的决定是否定的。
照片来自 Shutterstock
